NMPA Accepts Shanghai Fosun Pharmaceutical's Drug Registration Application

MT Newswires Live07-22

Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) cyanide poisoning drug registration application was accepted by China's National Medical Products Administration (NMPA), according to a Friday filing on the Hong Kong bourse.

The new drug, which was developed by the company's unit Chongqing Carelife Pharmaceutical, is for treating cyanide poisoning, as well as arsenic, mercury, lead, bismuth, and iodine poisoning.

The company shares are up by over 1% at the close of trading.

Price (HKD): $13.78, Change: $+0.20, Percent Change: +1.47%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment